



# NEWS RELEASE

## CONTACT:

Michele Rozen  
Pure Communications  
617-730-8284

### Catabasis Pharmaceuticals to Present at Upcoming Conferences

CAMBRIDGE, Mass. – October 19, 2011 – [Catabasis Pharmaceuticals](#), a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids to create therapeutics for the treatment of inflammatory and metabolic diseases, today announced that the company will present at the following upcoming conferences.

- [10th Annual BIO Investor Forum](#), being held Oct. 25-26 at the Palace Hotel in San Francisco, Calif. Jill C. Milne, Ph.D., co-founder and chief executive officer of Catabasis Pharmaceuticals, will give a company overview at 3:30 p.m. on Tuesday, Oct. 25.

The BIO Investor Forum is an international investor conference which assembles a select group of public and venture-stage growth companies, as well as top public and private equity investors. The mission of the forum is to support industry-wide success and present a broad and unbiased view of investment opportunities.

- [Discovery on Target 2011](#), being held Nov. 2-4 at the Park Plaza Hotel & Towers in Boston, Mass. Michael Jirousek, Ph.D., co-founder and chief scientific officer of Catabasis Pharmaceuticals, will serve as a moderator for the discussion “Exploring the Inflammation/Diabetes Connection” at 7:30 a.m. on Friday, Nov. 4 during an interactive breakfast breakout discussion group, as part of the conference’s Diabetes Drug Discovery track. This discussion will explore the issues of how inflammation and diabetes are connected, whether or not the inflammation and diabetes link for drug development can be targeted, and the pros and cons of focusing on inflammation to treat diabetes.

Also as part of the Diabetes Drug Discovery track of the Discovery on Target conference, Dr. Jirousek will give a presentation titled “Rebalancing Inflammation in Type 2 Diabetes: CAT1000 New Chemical Entities” at 4:40 p.m. on Friday, Nov. 4. This presentation will focus on the CAT1000 series of new chemical entities and the underlying inflammatory response in type 2 diabetes that is rebalanced and resolved by selective inhibition of pro-inflammatory pathways and activation of endogenous anti-inflammatory pathways.

## About Catabasis

Catabasis is a clinically staged company dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. Catabasis has developed a pipeline of molecules that amplify the beneficial effects of omega-3 fatty acids to target the underlying etiologies of a spectrum of complex human diseases. Catabasis’ approach dramatically enhances the therapeutic potential of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), two essential fatty acids found

in fish oil, by improving the delivery, potency and efficacy. The company was founded in 2008 and is headquartered in Cambridge, Mass. Please visit [www.catabasispharma.com](http://www.catabasispharma.com) for more information.

###